Perbedaan Brigit Biofarmaka Teknologi Tbk. dan Trimegah Karya Pratama Tbk.: Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp240 (kapitalisasi pasar 166,01 M, volume 24 jam 324 rb), sedangkan Trimegah Karya Pratama Tbk. diperdagangkan di Rp155 (kapitalisasi pasar 314,02 M, volume 24 jam 49,33 jt). Perbedaan utamanya: Trimegah Karya Pratama Tbk. lebih besar dari sisi kapitalisasi pasar, dan Trimegah Karya Pratama Tbk. lebih aktif diperdagangkan (49,33 jt vs 324 rb). Mana yang lebih baik tergantung tujuan investasimu.
| OBAT | UVCR | |
|---|---|---|
Kapitalisasi Pasar | 166,01 M | 314,02 M |
Volume | 324 rb | 49,33 jt |
Lot | 3,24 rb | 493,25 rb |
Perputaran | 77,68 jt | 7,55 M |
Harga Rata-rata | 239,75 | 153,12 |
Nilai Transaksi | 77,68 jt | 7,55 M |
Harga Ekuilibrium Indikatif | 240 | 155 |
Volume Ekuilibrium Indikatif | 1 | 3,77 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Selengkapnya di halaman UVCR →